- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02891720
Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM
September 1, 2016 updated by: Hektoen Institute for Medical Research
The goal of this study is to evaluate an integrated technology system that confirms ingestion of oral PrEP, monitors adherence both in real-time and longitudinally, and provides visual feedback mechanisms to promote enhanced adherence behaviors.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
In order to evaluate the feasibility and acceptability of the PSS for FTC/TDF PrEP, 100 HIV-negative YMSM will be randomized in the Advances in Technology to Enhance Adherence Monitoring (A-TEAM) pilot study to 12 weeks of daily FTC/TDF with the PSS versus daily FTC/TDF standard-of-care (SOC), then each arm will crossover to 12 weeks of daily FTC/TDF without the sensor system versus with the sensor system, respectively.
PrEP will be provided by the study (see Gilead letter) and other aspects of PrEP clinical care will be consistent with the PrEP Clinic's standard practices based on CDC clinical guidelines.
The detection accuracy of the PSS will be correlated with DBS-determined TFV-DP and FTC-TP levels obtained monthly from participants.
A relationship between TVF-DP in DBS and adherence to FTC/TDF PrEP in the preceding 1-3 months has previously been characterized.
These adherence categories were implemented in iPrEx OLE and consisted of: below lower limit of quantitation (BLQ), >BLQ to 349 fmol per punch (fewer than two tablets per week), 350-699 fmol per punch (two or three tablets per week), 700-1249 fmol per punch (four to six tablets per week), and 1250 fmol per punch or more (daily dosing).
Real-time visual feedback of medication ingestion will be provided to the participant via the PSS and transmitted to the study team.
A weekly text message with estimated HIV risk reduction based upon the DBS algorithm will be transmitted to participants after the initial first week of FTC/TDF dosing.
Finally, in-depth qualitative exploration of barriers and facilitators to use of the PSS components will be completed through individual interviews as well as focus group discussions with participants.
Participants will also provide feedback on text messages regarding PrEP protection as well as suggestions for other potential methods to receive performance data.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gregory Huhn, MD
- Phone Number: (312) 572-4575
- Email: ghuhn@cookcountyhhs.org
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 24 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria
Young men who meet all of the following criteria are eligible for inclusion:
- PrEP-eligible YMSM
- Ages 18-24
- Biologically born male
- Report interest in PrEP
- Intend to use PrEP for a full 6 month period
- Eligible to be a PrEP patient at the CORE Center PrEP Clinic
Meet one the following sexual risk criteria:
- Have an HIV-positive sexual partner
- Had recent bacterial STI
- Report high numbers of sexual partners
- Report history of inconsistent or no condom use
- Report exchange/transactional sex.
Exclusion Criteria
Young men who meet any of the following criteria will be excluded:
- HIV+
- Creatinine clearance <60 cc/min)
- Allergy to topical adhesive
- Acute gastrointestinal symptoms
- History of major GI surgery
- Presence of an implanted electronic medical device.
- Subjects who are receiving any of the following medications:Nephrotoxic drugs (e.g., cidofovir, amphotericin, aminoglycosides, dapsone, tacrolimus, foscarnet, ACE inhibitors), all diuretics, drugs that may interfere with TFV excretion (e.g., (Val)ganciclovir, Cyclosporin A, Sirolimus, Antineoplastics), drugs (not including mineral and vitamin supplements) used for treatment of osteoporosis (e.g., alendronate and other bisphosphonates, teriparatide, denosumab, and calcitonin), chronic use of oral or systemic steroids (i.e., daily use for two weeks or more is not allowed), experimental medications that are not Food and Drug Administration (FDA)-approved, and FTC/TDF (Truvada®) received outside of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ARM A: Proteus Sensor System (PSS) First
ARM A will receive Proteus Sensor System (PSS) first.
At 12-week intervals participants will crossover to the next condition.
|
The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
|
No Intervention: ARM B: SOC First
ARM B will 12 weeks of FTC/TDS standard of care (SOC) first.
At 12-week intervals participants will crossover to the next condition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of HIV-negative YMSM taking part in PSS intervention who adhere to PrEP medication
Time Frame: Up to 33 months
|
Up to 33 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2017
Primary Completion (Anticipated)
November 1, 2018
Study Completion (Anticipated)
November 1, 2019
Study Registration Dates
First Submitted
August 29, 2016
First Submitted That Met QC Criteria
September 1, 2016
First Posted (Estimate)
September 7, 2016
Study Record Updates
Last Update Posted (Estimate)
September 7, 2016
Last Update Submitted That Met QC Criteria
September 1, 2016
Last Verified
September 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- R01AI122308 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Findings from this study will provide pharmacokinetic data along with evidence of the feasibility and acceptability of the novel Proteus adherence monitoring system for use among young MSM who are highly vulnerable to HIV infection.
Audiences for dissemination are: 1) scientists; 2) primary and secondary prevention practitioners; and 3) YMSM, their partners, and their friends/families.
Traditional dissemination vehicles will be used including manuscripts and presentations at international and national meetings.
To facilitate integration of the findings into the public health arena, the protocol team will work closely with their YAB and present findings in forums attended by community-based organizations, such as local PrEP trainings and workshops.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusSpain, France, Germany
Clinical Trials on Proteus Sensor System
-
Scripps Translational Science InstituteScripps ClinicCompletedHeart Failure | Medication ComplianceUnited States
-
Centre Antoine LacassagneRecruitingOsteosarcoma | Ewing Sarcoma | Chondrosarcoma | ChordomaFrance
-
University of California, Los AngelesYale University; University of NebraskaCompletedHIV/AIDS | Medication AdherenceUnited States
-
Proteus Digital Health, Inc.Syneos HealthCompletedHypertension | Diabetes Mellitus, Type 2 | Hypercholesterolemia
-
University of Sao Paulo General HospitalZOLL Circulation, Inc., USAUnknownMyocardial Infarction | Hypothermia, Induced | Rewarming | Percutaneous Cornonary InterventionBrazil
-
Proteus Digital Health, Inc.Massachusetts General Hospital; The Zucker Hillside HospitalCompletedSchizophrenia | Bipolar DisorderUnited States
-
KK Women's and Children's HospitalCompletedPulmonary Aspiration of Gastric ContentsSingapore
-
Nisha ArenjaNot yet recruiting
-
St. Antonius HospitalCompletedErectile DysfunctionNetherlands
-
The University of Hong KongHaven of Hope Hospital; The Social Innovation and Entrepreneurship Development...Completed